HomeMESO • NASDAQ
add
Mesoblast Ltd
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 1.26M | -41.23% |
Operating expense | 6.11M | 5.44% |
Net income | -27.71M | -26.41% |
Net profit margin | -2.20K | -115.11% |
Earnings per share | — | — |
EBITDA | -15.26M | 17.72% |
Effective tax rate | 0.16% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 62.96M | -11.72% |
Total assets | 669.15M | -0.04% |
Total liabilities | 188.80M | 12.66% |
Total equity | 480.36M | — |
Shares outstanding | 1.14B | — |
Price to book | 40.90 | — |
Return on assets | -5.86% | — |
Return on capital | -6.55% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -27.71M | -26.41% |
Cash from operations | -10.94M | 32.77% |
Cash from investing | -4.50K | -128.12% |
Cash from financing | 4.33M | -88.84% |
Net change in cash | -7.30M | -132.40% |
Free cash flow | -10.19M | 53.48% |
About
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004. Wikipedia
Founded
2004
Website
Employees
73
